FTC probes Mylan about settlement with Cephalon over modafinil
Cephalon Inc. (CEPH) entered an agreement related to patent-infringement litigation with Mylan Laboratories, granting Mylan Laboratories non-exclusive, royalty-bearing rights to market and sell modafinil in the U.S.
Cephalon also entered separate agreements with Teva Pharmaceuticals USA Inc. (TEVA), Ranbaxy Pharmaceuticals Inc. and Barr Laboratories Inc. (BRL).
According to Mylan Laboratories' quarterly report filed Friday with the Securities and Exchange Commission, the FTC requested information from the company and certain subsidiaries related to the patent litigation and settlement with Cephalon in a letter dated July 11. Mylan Laboratories said that beginning in April, it and four other drug manufacturers were also named in a series of civil lawsuits tied to the modafinil patent-litigation settlement agreements.
Cephalon also entered separate agreements with Teva Pharmaceuticals USA Inc. (TEVA), Ranbaxy Pharmaceuticals Inc. and Barr Laboratories Inc. (BRL).
According to Mylan Laboratories' quarterly report filed Friday with the Securities and Exchange Commission, the FTC requested information from the company and certain subsidiaries related to the patent litigation and settlement with Cephalon in a letter dated July 11. Mylan Laboratories said that beginning in April, it and four other drug manufacturers were also named in a series of civil lawsuits tied to the modafinil patent-litigation settlement agreements.
posted by Lawrence B. Ebert at 3:08 PM
0 Comments:
Post a Comment
<< Home